RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma
This study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA...
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/28840 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.28840 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.288402018-09-24T16:37:51Z RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma Pensri Saelee Sopit Wongkham Sunanta Chariyalertsak Songsak Petmitr Ubol Chuensumran National Cancer Institute Thailand Khon Kaen University Mahidol University Suan Dusit University Biochemistry, Genetics and Molecular Biology Medicine This study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA levels were analyzed by quantitative real-time reverse transcription-PCR. Aberrant methylation of RASSF1A was detected in 25 of 29 cases (86%), with loss of RASSF1A expression evident in 8 of 22 cases (36%). No correlation between loss of RASSF1A mRNA and promoter hypermethylation of the RASSF1A gene was observed. There was a significant correlation between the methylation status of RASSF1A and hepatocellular carcinoma (HCC) patients who did not undergo chemotherapy (P = 0.03). Multivariate analysis, adjusted for tumor size, treatment, RASSF1A hypermethylation, and RASSF1A under-expression, showed RASSF1A hypermethylation to be assocaited with a better prognosis for HCC patients (HR= 0.089, 95%CI = 0.013-0.578; P = 0.012). Our findings showed that RASSF1A promoter hypermethylation occurs frequently, and may serve as a good prognostic factor. 2018-09-24T08:49:49Z 2018-09-24T08:49:49Z 2010-01-01 Article Asian Pacific Journal of Cancer Prevention. Vol.11, No.6 (2010), 1677-1681 2476762X 15137368 2-s2.0-79956136713 https://repository.li.mahidol.ac.th/handle/123456789/28840 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79956136713&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Biochemistry, Genetics and Molecular Biology Medicine |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Medicine Pensri Saelee Sopit Wongkham Sunanta Chariyalertsak Songsak Petmitr Ubol Chuensumran RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
description |
This study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA levels were analyzed by quantitative real-time reverse transcription-PCR. Aberrant methylation of RASSF1A was detected in 25 of 29 cases (86%), with loss of RASSF1A expression evident in 8 of 22 cases (36%). No correlation between loss of RASSF1A mRNA and promoter hypermethylation of the RASSF1A gene was observed. There was a significant correlation between the methylation status of RASSF1A and hepatocellular carcinoma (HCC) patients who did not undergo chemotherapy (P = 0.03). Multivariate analysis, adjusted for tumor size, treatment, RASSF1A hypermethylation, and RASSF1A under-expression, showed RASSF1A hypermethylation to be assocaited with a better prognosis for HCC patients (HR= 0.089, 95%CI = 0.013-0.578; P = 0.012). Our findings showed that RASSF1A promoter hypermethylation occurs frequently, and may serve as a good prognostic factor. |
author2 |
National Cancer Institute Thailand |
author_facet |
National Cancer Institute Thailand Pensri Saelee Sopit Wongkham Sunanta Chariyalertsak Songsak Petmitr Ubol Chuensumran |
format |
Article |
author |
Pensri Saelee Sopit Wongkham Sunanta Chariyalertsak Songsak Petmitr Ubol Chuensumran |
author_sort |
Pensri Saelee |
title |
RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
title_short |
RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
title_full |
RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
title_fullStr |
RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
title_full_unstemmed |
RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
title_sort |
rassf1a promoter hypermethylation as a prognostic marker for hepatocellular carcinoma |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/28840 |
_version_ |
1763489343699156992 |